CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
"Medidata is at the forefront of a critical shift in the life sciences sector," said Anthony Costello, CEO, Medidata. "By harnessing AI-powered solutions and partnering with visionaries, we aren't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback